SALT LAKE CITY--(BUSINESS WIRE)--A study published in the August issue of Journal of Clinical Microbiology showed that Great Basin Corporation’s toxigenic Clostridium difficile (C. diff) molecular diagnostic test has a 97 percent sensitivity and 100 percent specificity rate compared with a competing FDA-approved polymerase chain reaction (PCR) test. In May, the U.S. Food and Drug Administration (FDA) granted 510(k) clearance for Great Basin’s C. diff assay.
